On thebmj.com today, two doctors debate whether research fraud should be classed as a criminal act.
On thebmj.com today, two doctors debate whether research fraud should be classed as a criminal act.
Dr Zulfiqar Bhutta, Robert Harding Chair in global child health and policy and Co-Director of the Centre for Global Child Health at the Hospital for Sick Children, Toronto believes that criminal sanctions are necessary to deter growing research misconduct.
He says the fact that research fraud is common is no longer news, but a review by PubMed in 2012 found that 67% of research article retractions were “attributable to scientific misconduct, including fraud or suspected fraud”.
Dr Bhutta says the consequences of research fraud on human health can be “huge” and that the damage to global vaccination coverage by Andrew Wakefield “has been incalculable”. Wakefield, however, lives a free man, “raking in money from various support groups.” Criminal proceedings after serious research fraud are rare with such practice being dealt with by institutions, he adds.
Although many think this is fair, given that it is hard to differentiate between fraud and incompetence, errors and misunderstanding, he argues that that “deliberate fraud is often prevalent.” Plus, investigations are often expensive, costing between $116,160 and $2,192,620 per case.
Current measures are not enough, he says. "Although many perpetrators of research fraud never return to academic life; others may claw their way back to active research."
Bhutta concludes that although the costs of fraud are not known, “human, social and economic costs are likely considerable” and that "additional deterrence through punitive measures such as criminal proceedings should be added to the repertoire of measures available."
He concludes that because consequences can be huge, "it is time to regard such behaviour in the same category as criminal fraud and deal with it accordingly."
But Dr Julian Crane from the Department of Medicine at the University of Otago in New Zealand, argues that criminalisation would not have any deterrent effect and would undermine trust rather than improve it.
Crane says the former editor of The BMJ Richard Smith recently defined research misconduct as “the gentlemanly phrase for scientific fraud” and asks who “would not have fallen foul of this definition, so are we all fraudsters?"
Smith says research is “terrifyingly common” but only one in every 18,234 published abstracts are retracted because of real or suspected misconduct, which Crane adds “seems refreshingly small”.
Crane appreciates that research misconduct does cause harm, but asks “would inviting the police to investigate more satisfactorily uncover misconduct or prevent harm?"
He believes that it lies with research organisations to reduce opportunities for misconduct and investigate appropriately. He concludes that criminalising research misconduct "is a sad, bad, even mad idea that will only undermine the trust that is an essential component of research and requires good governance not criminal investigators."
Read the debate here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.